|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
11.04.26 - 04:03
|
Soleno Therapeutics, Inc. Notice of May 5, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline (PR Newswire)
|
|
|
NEW YORK and NEW ORLEANS, April 10, 2026 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NasdaqCM: SLNO) of a class action securities......
|
|
|
|
|
|
|
|
|
08.04.26 - 22:24
|
Soleno Therapeutics, Inc. (SLNO) Investors: May 5, 2026, Deadline in Securities Fraud Class Action Lawsuit (PR Newswire)
|
|
|
Did you buy SLNO common stock between March 26, 2025, and November 4, 2025? Affected Soleno Therapeutics, Inc. Investor Summary Who: Soleno Therapeutics, Inc. (NASDAQ: SLNO) What: Securities fraud class action lawsuit filed Class Period: March 26, 2025, through November 4, 2025 Deadline......
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
07.04.26 - 12:24
|
Neurocrine to acquire Soleno in $2.9bn transaction (PBR)
|
|
|
The transaction will expand Neurocrine's portfolio in endocrinology and rare diseases via the addition of Soleno's lead product, Vykat XR (diazoxide choline), for Prader-Willi syndrome (PWS). Vykat XR
The post Neurocrine to acquire Soleno in $2.9bn transaction appeared first on Pharmaceutical Business review....
|
|